Pharmacoeconomic Analysis of Drugs Used in the Treatment of Pneumonia in Paediatric Population in a Tertiary Care Hospital in India—A Cost-of-Illness Study by Lekha Saha, Sweta Kumari, Pratibha Khosla, Alka Rani, Sharonjeet Kaur

Get full text

A Pharmacoeconomics Study for Anticoagulants used for Hospitalized COVID-19 Patients in Al-Najaf Al-Ashraf city –Iraq(Conference Paper )# by Fatimah Baqer Alqubbanchi, Fadya Yaqoob Al-Hamadani

Subjects: “…pharmacoeconomic cost-effectiveness, covid-19, anticoagulants, heparin, enoxaparin…”
Get full text

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis by Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo

Get full text

PERAMPANEL EFFECTIVENESS IN THE TREATMENT OF REFRACTERY PARTIAL ONSET EPILEPSY WITH OR WITHOUT SECONDARY GENERALIZATION: PHARMACOECONOMIC ANALYSIS FOR THE RUSSIAN FEDERATION HEALTH CARE SYSTEM by N. K. Mazina, I. V. Sheshunov, P. V. Мazin, Yu. V. Kislitsin, E. M. Markova

Subjects: Get full text

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION by A. V. Rudakova, D. A. Gusev, A. N. Uskov, L. N. Konovalova, Yu. V. Lobzin

Get full text

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis by Dranitsaris G, Shane LG, Crowther M, Feugere G, Woodruff S

Get full text

Clinical and pharmacoeconomic profile of COPD patients with FEV1 50—60% predicted: pilot study on the impact of the extended indication of ICS/LABA by Roberto Walter Dal Negro, Luca Bonadiman, Claudio Turati, Paola Turco

Get full text

Pharmacoeconomic analysis of biologics and methotrexate for rheumatoid arthritis from the standpoint of the number needed to treat concept under the Japanese health insurance system by Kengo Harigane, Yuichi Mochida, Takayuki Shimazaki, Naomi Kobayashi, Yutaka Inaba

Get full text

Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases by A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, D. R. Naskhletashvili

Get full text

Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity by A. R. Kasimova, A. S. Kolbin, M. A. Proskurin, Yu. E. Balykina

Subjects: Get full text

A pharmacoeconomic analysis to compare cost-effectiveness of metformin plus teneligliptin with metformin plus glimepiride in patients of type-2 diabetes mellitus by Tanya Tandon, Ashok K Dubey, Saurabh Srivastava, Sachin Manocha, Ekta Arora, Nazer Hasan

Get full text

Pharmacoeconomic efficacy of atesolizumab compared with other PD-1 inhibitors in patients with advanced non-small cell lung cancer after chemotherapy by S. K. Zyryanov, I. N. Diyakov

“…The use of the atesolizumab preparation is pharmacoeconomically reasonable and appropriate in comparison with the use of nivolumab and pembrolizumab. …”
Get full text

The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study by B Polistena, F Spandonaro, R Capra, S Fantaccini, L Santoni, GB Zimatore, C Gasperini

Get full text

Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. by Cassidy, J, Douillard, J, Twelves, C, McKendrick, J, Scheithauer, W, Bustová, I, Johnston, P, Lesniewski-Kmak, K, Jelic, S, Fountzilas, G, Coxon, F, Díaz-Rubio, E, Maughan, T, Malzyner, A, Bertetto, O, Beham, A, Figer, A, Dufour, P, Patel, K, Cowell, W, Garrison, L

“…Cost savings and better outcomes make capecitabine a preferred adjuvant therapy for Dukes' C colon cancer. This pharmacoeconomic analysis strongly supports replacing 5-FU/LV with capecitabine in the adjuvant treatment of colon cancer in the UK.…”

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events by O. V. Shatalova

Subjects: “…pharmacoeconomics…”
Get full text

Outcomes research and drug development by Sandeep Duttagupta

Subjects: Get full text

Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis by Anne Kangethe, Debra F. Lawrence, Maëlys Touya, Lambros Chrones, Michael Polson, Themmi Evangelatos

Subjects: Get full text

Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients by Yun Kim, Soohyun Kim, Jinsook Park, Howard Lee

Subjects: Get full text

Evaluating the Use of Dalbavancin for Off-Label Indications by Katherine Taylor, John Williamson, Vera Luther, Tyler Stone, James Johnson, Zachary Gruss, Courtney Russ-Friedman, Chris Ohl, James Beardsley

Subjects: Get full text

Drug costs in context: assessing drug costs in cost-of-illness analyses by T Joseph Mattingly II, Shannon Weathers

Subjects: Get full text